We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (... 4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease. Show more
Ask ADVFN Intelligence (AI)
Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic...
Landmark publication in leading ophthalmology research journal demonstrates the power of 4DMT’s Therapeutic Vector Evolution platform to invent potentially best-in-class customized vectors and...
EMERYVILLE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.36 | -22.8956228956 | 5.94 | 6.015 | 4.58 | 771001 | 4.95356934 | CS |
| 4 | -1.22 | -21.0344827586 | 5.8 | 6.666 | 4.58 | 1040650 | 5.75708364 | CS |
| 12 | -3.69 | -44.6191051995 | 8.27 | 9.1799 | 4.58 | 882302 | 6.94553366 | CS |
| 26 | -24.31 | -84.146763586 | 28.89 | 28.9269 | 4.58 | 953733 | 11.02121048 | CS |
| 52 | -13.57 | -74.7658402204 | 18.15 | 36.25 | 4.58 | 915033 | 18.74891978 | CS |
| 156 | -11.95 | -72.2928009679 | 16.53 | 36.25 | 4.58 | 550481 | 17.38105165 | CS |
| 260 | -35.42 | -88.55 | 40 | 55.11 | 4.58 | 455039 | 18.91516908 | CS |
Monksdream
4 weeks ago
Monksdream
3 months ago
Monksdream
3 months ago
Biggeoff
11 months ago
Monksdream
11 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
